Thrombin Expression in Prostate: A Novel Finding

被引:13
作者
Kohli, Manish [1 ]
Williams, Karin [2 ]
Yao, Jorge L. [3 ]
Dennis, Richard A. [4 ]
Huang, Jiaoti [5 ]
Reeder, Jay [6 ]
Ricke, William A. [7 ]
机构
[1] Mayo Clin, Dept Oncol, Rochester, MN USA
[2] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH USA
[3] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA
[4] Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA
[6] SUNY Upstate Med Univ, Dept Urol, Syracuse, NY USA
[7] Univ Rochester, Med Ctr, Dept Urol & Pathol & Lab Med, Rochester, NY 14642 USA
关键词
MOLECULAR-WEIGHT HEPARIN; VENOUS THROMBOEMBOLISM; TISSUE FACTOR; CANCER; ACTIVATION; MALIGNANCY; SURVIVAL; DISEASE; METASTASIS; CARCINOMA;
D O I
10.3109/07357907.2010.535057
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: A variable repertoire of coagulation protein expression is observed in different cancers. We evaluated expression of thrombin in prostate tissue. Methods: Detection of thrombin was performed using quantitative real-time PCR in fresh tissue and in situ hybridization (ISH) in archival prostate tissue and by immunohistochemistry of prostate tissue microarrays. Results: (Pro)thrombin mRNA expression was detected in cancer tissue and localized to prostatic epithelium and stroma by ISH. Thrombin protein was detected in stroma of benign and malignant epithelium (p <.05). Conclusions: Prostate tissue is a rich reservoir of thrombin. This may have potential for developing antithrombin-based cancer therapy.</.
引用
收藏
页码:62 / 67
页数:6
相关论文
共 24 条
[11]  
Kaushal V, 2008, APPL IMMUNOHISTO M M, V16, P1
[12]   Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism [J].
Lee, AYY ;
Rickles, FR ;
Julian, JA ;
Gent, M ;
Baker, RI ;
Bowden, C ;
Kakkar, AK ;
Prins, M ;
Levine, MN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2123-2129
[13]   Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy - Risk analysis using Medicare claims data [J].
Levitan, N ;
Dowlati, A ;
Remick, SC ;
Tahsildar, HI ;
Sivinski, LD ;
Beyth, R ;
Rimm, AA .
MEDICINE, 1999, 78 (05) :285-291
[14]   Increased incidence of neoplasia with persistent activation of the of the digestive tract in men coagulant pathway [J].
Miller, GJ ;
Bauer, KA ;
Howarth, DJ ;
Cooper, JA ;
Humphries, SE ;
Rosenberg, RD .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (12) :2107-2114
[15]  
Shi XL, 2004, MOL CANCER RES, V2, P395
[16]   Prognosis of cancers associated with venous thromboembolism. [J].
Sorensen, HT ;
Mellemkjær, L ;
Olsen, JH ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (25) :1846-1850
[17]   PAR1-mediated NFκB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism [J].
Tantivejkul, K ;
Loberg, RD ;
Mawocha, SC ;
Day, LL ;
St John, L ;
Pienta, BA ;
Rubin, MA ;
Pienta, KJ .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2005, 96 (03) :641-652
[18]  
WOJTUKIEWICZ MZ, 1991, CANCER-AM CANCER SOC, V67, P1377, DOI 10.1002/1097-0142(19910301)67:5<1377::AID-CNCR2820670517>3.0.CO
[19]  
2-2
[20]   Activation of the coagulation system in cancerogenesis and metastasation [J].
Xie, WZ ;
Leibl, M ;
Clark, MR ;
Dohrmann, P ;
Kunze, T ;
Gieseler, F .
BIOMEDICINE & PHARMACOTHERAPY, 2005, 59 (03) :70-75